We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first... Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Show more
BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (βCocrystalβ or the βCompanyβ) reports financial results for the three and nine months ended September 30...
The Companyβs antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current influenza vaccines offer no protection...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.42 | 20 | 2.1 | 2.69 | 1.9 | 76613 | 2.36813244 | CS |
4 | 0.39 | 18.3098591549 | 2.13 | 2.69 | 1.81 | 31457 | 2.2243545 | CS |
12 | 0.79 | 45.6647398844 | 1.73 | 2.69 | 1.65 | 24431 | 2.06591347 | CS |
26 | -0.17 | -6.31970260223 | 2.69 | 2.7804 | 1.6 | 22098 | 2.05763578 | CS |
52 | 0.73 | 40.782122905 | 1.79 | 3.1 | 1.325 | 21818 | 2.00175938 | CS |
156 | -6.18 | -71.0344827586 | 8.7 | 8.88 | 1.325 | 106504 | 5.07427708 | CS |
260 | -2.64 | -51.1627906977 | 5.16 | 49.2 | 1.325 | 2048554 | 18.85879322 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions